Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NSPR 
InspireMD Inc (NSPR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: NSPR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.5
1 Year Target Price $4.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -8.14% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 69.54M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 2 | Beta 0.61 | 52 Weeks Range 1.99 - 3.80 | Updated Date 06/30/2025 |
52 Weeks Range 1.99 - 3.80 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.77 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -749.51% |
Management Effectiveness
Return on Assets (TTM) -58.16% | Return on Equity (TTM) -113.95% |
Valuation
Trailing PE - | Forward PE 11.7 | Enterprise Value 46390942 | Price to Sales(TTM) 9.9 |
Enterprise Value 46390942 | Price to Sales(TTM) 9.9 | ||
Enterprise Value to Revenue 6.6 | Enterprise Value to EBITDA 0.52 | Shares Outstanding 30635300 | Shares Floating 16384396 |
Shares Outstanding 30635300 | Shares Floating 16384396 | ||
Percent Insiders 28.43 | Percent Institutions 42.16 |
Analyst Ratings
Rating 2 | Target Price 4.5 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
InspireMD Inc
Company Overview
History and Background
InspireMD, Inc. is a medical device company focused on the development and commercialization of proprietary MicroNet stent technologies. Founded in 2005, it has evolved from focusing on neurovascular applications to broader vascular indications. Significant milestones include obtaining regulatory approvals for its CGuard Embolic Prevention System (EPS) in Europe and other regions.
Core Business Areas
- Carotid Artery Stenting: Develops and markets the CGuard EPS for the prevention of stroke during carotid artery stenting procedures.
- Peripheral Artery Disease (PAD): Focuses on developing solutions for PAD, including stents and delivery systems.
- Research and Development: Conducts ongoing research and development efforts to expand its product portfolio and improve existing technologies.
Leadership and Structure
Leadership includes CEO, CFO, and other key executives. The organizational structure is typical of a small medical device company, with departments focused on R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- CGuard EPS: A carotid stent system designed to prevent embolic events during carotid artery stenting. Market share data varies by region and is difficult to ascertain precisely, but the product is gaining traction in Europe and emerging markets. Competitors include Boston Scientific (BSX), Abbott (ABT), and Medtronic (MDT).
Market Dynamics
Industry Overview
The medical device industry is highly competitive and regulated, with significant growth driven by aging populations, increasing prevalence of cardiovascular diseases, and technological advancements.
Positioning
InspireMD is a niche player in the carotid artery stenting market, focusing on embolic protection. Its competitive advantage lies in its MicroNet technology, designed to prevent distal embolization.
Total Addressable Market (TAM)
The global carotid artery stenting market is estimated to be worth billions of dollars. InspireMD is positioned to capture a share of this market with its innovative CGuard EPS, though precise TAM penetration is reliant on regulatory approvals and market adoption.
Upturn SWOT Analysis
Strengths
- Proprietary MicroNet technology
- CE Mark approval for CGuard EPS
- Focus on embolic protection
- Potential for growth in emerging markets
Weaknesses
- Limited market share
- Dependence on single product (CGuard EPS)
- Relatively small size compared to major competitors
- Historical financial losses
Opportunities
- Expansion into new geographic markets
- Development of new applications for MicroNet technology
- Potential for partnerships or acquisitions
- Increasing awareness of embolic protection during carotid stenting
Threats
- Competition from larger medical device companies
- Regulatory hurdles
- Reimbursement pressures
- Technological obsolescence
Competitors and Market Share
Key Competitors
- BSX
- ABT
- MDT
Competitive Landscape
InspireMD's CGuard EPS offers a unique embolic protection feature. However, it faces intense competition from larger, more established companies with broader product portfolios and greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been uneven, with periods of rapid revenue growth followed by periods of slower growth or decline.
Future Projections: Future growth depends on the success of CGuard EPS in existing markets, expansion into new markets, and development of new products. Analyst estimates are unavailable at this time.
Recent Initiatives: Recent initiatives include efforts to expand sales and marketing efforts for CGuard EPS, pursue regulatory approvals in new markets, and advance research and development programs.
Summary
InspireMD is a small medical device company with a unique product offering (CGuard EPS) for stroke prevention during carotid artery stenting. While it has regulatory approvals in certain markets, it faces significant challenges from larger competitors and requires successful market penetration and financial stability. Financial Losses and low market share remains as threats.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Press releases
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InspireMD Inc
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 2011-04-12 | President, CEO & Director Mr. Marvin L. Slosman | ||
Sector Healthcare | Industry Medical Devices | Full time employees 66 | Website https://www.inspiremd.com |
Full time employees 66 | Website https://www.inspiremd.com | ||
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as well as treating acute stroke with tandem lesions. It has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.